Business

Nanopharmaceutics and Northwestern University Announce Initiation of Phase I Adaptive Dose Escalation Clinical Study with Dose Expansion of Oral Triapine® in Combination with Temozolomide (TMZ) for Pa

Nanopharmaceutics and Northwestern University Announce Initiation of Phase I Adaptive Dose Escalation Clinical Study with Dose Expansion of Oral Triapine® in Combination with Temozolomide (TMZ) for Pa.

articleTron Group Inc.May 14, 20243/company/tron-group-inc/news/nanopharmaceutics-and-northwestern-university-announce-initiation-of-phase-i-adaptive-dose-escalation-clinical-study-with-dose-expansion-of-oral-triapiner-in-combination-with-temozolomide-tmz-for-pa
Nanopharmaceutics and Northwestern University Announce Initiation of Phase I Adaptive Dose Escalation Clinical Study with Dose Expansion of Oral Triapine® in Combination with Temozolomide (TMZ) for Pa

About this update from Tron Group Inc.

[{"type":"text","content":"","length":30,"tagName":"div"}]

More updates from Tron Group Inc.